Fig. 4From: Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trialCost-effectiveness acceptability curves showing the probability of simvastatin being cost-effective compared to placebo for the primary and sensitivity analyses. EQ-5D-3L EuroQol Five Dimension (Three Level), QALY quality-adjusted life yearBack to article page